compound 12c

Compound 12c is a novel benzimidazolone-bridged hybrid small molecule featuring a coumarin substituent, developed as a potential antineoplastic agent. In preclinical evaluations, it demonstrated significant antiproliferative activity against several human cancer cell lines, including lung (A549), breast (MCF-7), and cervical (HeLa) cancer, with HeLa cells showing the highest sensitivity. Molecular docking studies indicate that compound 12c acts as a dual inhibitor, targeting Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) and Cyclin-Dependent Kinase 4 (CDK4). Notably, it exhibited the highest predicted affinity for VEGFR2 within its structural series. Furthermore, the compound shows a favorable selectivity profile, with a high selectivity index (SI) indicating lower toxicity toward non-cancerous HEK293 cells compared to malignant cells.